Qualigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
15 September 2021 - 9:30PM
Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company
focused on developing treatments for adult and pediatric cancers
with potential for Orphan Drug Designation, announced today that
CEO and Chairman Michael Poirier will present at the Oppenheimer
Fall Healthcare Life Sciences & MedTech Summit September 20-23,
2021.
The presentation will provide an overview of the
Company’s strategy focusing primarily on its oncology drug pipeline
which includes QN-247 and RAS-F assets for which Qualigen has
already seen encouraging preclinical data.
Qualigen Therapeutics,
Inc. Presentation Details are as
follows:
Format: Virtual
Presentation Webcast: www.qualigeninc.com/opco21
Presentation Time: Wednesday, September 22, 2021, 4:35 pm EDT.
The webcast link will broadcast the presentation live, and can be
viewed for 90 days thereafter.
Virtual Meetings: One-on-one meetings will be
held virtually and will be available to registered attendees.
Qualigen Management will be available throughout each day September
20-22, 2021. Contact your Oppenheimer representative to register.
You may also email opcoconferences@opco.com to register.
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc. is a biotechnology
company focused on developing treatments for adult and pediatric
cancers with potential for Orphan Drug Designation. Qualigen’s
aptamer platform, of which QN-247 is the lead candidate, inhibits
nucleolin, a key multi-functional regulatory protein that is
overexpressed in cancer cells, thus influencing their
proliferation, survival and metastasis. QN-247 has shown promise in
pre-clinical studies for the treatment of acute myeloid leukemia
(AML). Qualigen’s RAS-F platform is a family of RAS oncogene
protein-protein interaction inhibitor small molecules that is
believed to disrupt pathways for cancer genes that cause tumor
formation. Such mechanism of action may be effective in the
treatment of about one quarter of all cancers, including certain
forms of pancreatic, colorectal, and lung cancers. The RAS pathway
has generated considerable interest due to recent breakthrough
developments in the field and the first clinical approval earlier
this year for a K-RAS directed drug. In addition to its oncology
drug pipeline, Qualigen has an established diagnostics business
which manufactures and distributes proprietary and highly accurate
rapid blood testing systems for the management of prostate cancer
and other diseases and health conditions. Qualigen’s management has
significant experience in drug and medical device development,
manufacturing, marketing and distribution.
For more information about Qualigen Therapeutics, Inc. please
visit www.qualigeninc.com.
Forward-Looking Statements
This news release contains forward-looking
statements by the Company that involve risks and uncertainties and
reflect the Company's judgment as of the date of this release.
These statements include those related to the Company's prospects
and strategy for the development of therapeutic drug candidates.
Actual events or results may differ from the Company's
expectations. For example, there can be no assurance that the
Company will develop any drugs (including QN-247 and RAS-F); that
preclinical or clinical development of the Company's drugs
(including QN-247 and RAS-F, and deprioritized infectious-disease
programs such as QN-165) will be completed on any projected
timeline or will be successful; that any clinical trials will be
approved to begin by or will proceed as contemplated by any
projected timeline; that future clinical trial data will be
favorable or that such trials will confirm any improvements over
other products or lack negative impacts; that any drugs will
receive required regulatory approvals (including Orphan Drug
status) or that they will be commercially successful; that patents
will issue on the Company's owned and in-licensed patent
applications; that such patents, if any, and the Company's
currently owned and inlicensed patents would prevent competition;
that the Company will be able to procure or earn sufficient working
capital to complete the development, testing and launch of the
Company's prospective therapeutic products (including QN-247 and
RAS-F, and any repositioning of QN-165); or that the Company will
be able to maintain or expand market demand and/or market share for
the Company's diagnostic products. The Company's stock price could
be harmed if any of the events or trends contemplated by the
forward-looking statements fails to occur or is delayed or if any
actual future event otherwise differs from expectations. Additional
information concerning these and other risk factors affecting the
Company's business can be found in the Company's prior filings with
the Securities and Exchange Commission, including its most recent
Form 10-K, all of which are available at www.sec.gov.
The Company disclaims any intent or obligation
to update these forward-looking statements beyond the date of this
news release, except as required by law. This caution is made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.
Investor Relations:
For further information: David KugelmanAtlanta Capital Partners,
LLC(404) 856-9157 or (866) 692-6847 Toll Free - U.S. &
Canadadk@atlcp.com
Tony SchorInvestor Awareness, Inc.(847)
971-0922tony@investorawareness.com
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Apr 2023 to Apr 2024